Atopic Dermatitis

TRIAL 75 (SUMMARY)

PRELIMINARY STUDY ON EFFECTS OF KLUYVEROMYCES B0399 ON PATIENTS WITH ATOPIC DERMATITIS

Prof. A. Tulli – Director of the Clinic of Dermatology, University of Studies “G. d’Annunzio” Chieti (Italy)


INTRODUCTION

The study was conducted on the basis of recent considerations on patients affected by atopic dermatitis. In about 80% of these patients a reduction in the efficiency of cellular immunity was observed, along with an elevated increase of total IgE. This could explain why atopic and non-atopic patients have a different distribution of subclasses of T lymphocytes. Given that T lymphocytes are divided into two types - Th1 cells which produce IL2 and IFN gamma and Th2 cells which produce interleucine IL 4,5,6 and 10 - and given that IFN gamma inhibits the IgE which are induced by the IL4, it was found that patients with atopic dermatitis had very low levels of IFN gamma and therefore a tendency toward a high level of IgE. This high level of IgE induces a hypersensitivity of the disease with critical consequences of the pathogenesis itself.

METHOD OF STUDY

Ten (10) patients with atopic dermatitis and with high seric levels of IgE, between the ages of 6 and 10, were treated orally with capsules containing the active ingredient Kluyveromyces marxianus fragilis B0399 (typified lactic yeasts: KLUYVER B0399).
Dosage: 1 capsule a day for 30 days. During the treatment the normal specific therapies were also applied.
After 30 days the seric levels of the IgE of the patients were controlled and showed a normal range of total IgE .

CONCLUSION

The results obtained show that the administration of Kluyveromyces B0399 favors the therapeutic action. This oral therapy with exogenous microorganisms (lactic yeasts KLUYVER B0399) can be a valid aid and adjuvant in atopic dermatitis , with an improvement of the coenaesthesia of the patient.